Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep-Oct;21(5):502-510.
doi: 10.21873/cgp.20467.

Impacts of Matrix Metalloproteinase-2 Promoter Genotypes on Breast Cancer Risk

Chih-Chiang Hung #  1 , Chung-Lin Tsai #  2 , Yu-Ting Chin #  3   4 , Yun-Chi Wang  3   4 , Chia-Hua Liu  1 , Meng-Liang Lin  5 , Shih-Shun Chen  6 , Jie-Long He  7 , Chia-Wen Tsai  3   4 , Chen-Hsien Su  4 , DA-Tian Bau  8   4   9 , Wen-Shin Chang  10   4
Affiliations

Impacts of Matrix Metalloproteinase-2 Promoter Genotypes on Breast Cancer Risk

Chih-Chiang Hung et al. Cancer Genomics Proteomics. 2024 Sep-Oct.

Abstract

Background/aim: Matrix metalloproteinase-2 (MMP-2) has been implicated in the pathogenesis of breast cancer (BC). However, there is limited research on the role of MMP-2 genotypes in BC risk. This study aimed to investigate the associations between two MMP-2 promoter polymorphisms, rs243865 and rs2285053, and BC risk.

Materials and methods: MMP-2 genotypes were analyzed using PCR-based RFLP methodology in a cohort comprising 1,232 BC cases and 1,232 controls.

Results: Genotypic frequencies of MMP-2 rs243865 and rs2285053 in controls were consistent with Hardy-Weinberg equilibrium (p=0.3702 and 0.2036, respectively). There were no significant differences in the distribution of rs243865 and rs2285053 genotypes between BC cases and controls (p for trend=0.1602 and 0.2170, respectively). Variant genotypes at rs243865 and rs2285053 appeared to confer a protective effect, although not statistically significant (all p>0.05). Similarly, the variant T allele at rs243865 and rs2285053 showed a non-significant trend towards decreased BC risk (OR=0.84 and 0.89, 95%CI=0.69-1.02 and 0.78-1.02, p=0.0811 and 0.1043, respectively). There was no interaction observed between MMP-2 rs243865 or rs2285053 genotypes and age. Stratified analysis did not reveal significant associations between MMP-2 rs243865 or rs2285053 genotypes and triple-negative breast cancer (TNBC) (p=0.6458 and 0.8745, respectively). Among both TNBC and non-TNBC cases, none of the variant genotypes at rs243865 or rs2285053 showed significant associations with TNBC (all p>0.05).

Conclusion: MMP-2 rs243865 and rs2285053 genotypes appear to have a minimal impact on individual susceptibility to BC or TNBC.

Keywords: Breast cancer; genotype; matrix metalloproteinase-2; polymorphism; triple negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The Authors declare no conflicts of interest in relation to this study.

Figures

Figure 1
Figure 1
Physical map of matrix metalloproteinase-2 (MMP-2) rs243865 and rs2285053 polymorphic sites.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, Zeng H, Zhou J, Wei W. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond) 2021;41(11):1183–1194. doi: 10.1002/cac2.12207. - DOI - PMC - PubMed
    1. Papadimitriou N, Dimou N, Gill D, Tzoulaki I, Murphy N, Riboli E, Lewis SJ, Martin RM, Gunter MJ, Tsilidis KK. Genetically predicted circulating concentrations of micronutrients and risk of breast cancer: A Mendelian randomization study. Int J Cancer. 2021;148(3):646–653. doi: 10.1002/ijc.33246. - DOI - PMC - PubMed
    1. Syrnioti A, Petousis S, Newman LA, Margioula-Siarkou C, Papamitsou T, Dinas K, Koletsa T. Triple negative breast cancer: molecular subtype-specific immune landscapes with therapeutic implications. Cancers (Basel) 2024;16(11):2094. doi: 10.3390/cancers16112094. - DOI - PMC - PubMed
    1. Haney MJ, Zhao Y, Jin YS, Li SM, Bago JR, Klyachko NL, Kabanov AV, Batrakova EV. Macrophage-derived extracellular vesicles as drug delivery systems for triple negative breast cancer (TNBC) therapy. J Neuroimmune Pharmacol. 2020;15(3):487–500. doi: 10.1007/s11481-019-09884-9. - DOI - PubMed

Substances

LinkOut - more resources